Shortages and concerns arise as weight-loss injections gain popularity
Weight-loss injections like Ozempic and Wegovy have gained significant attention, European startups entering market
Weight-loss injections like Ozempic and Wegovy have gained significant attention, even from celebrities like Elon Musk and Amy Schumer. European startups are entering the market to provide treatment plans using semaglutide, the active ingredient in these medications.
However, the surge in demand for semaglutide is causing concerns, particularly for diabetic patients, as the drug becomes less accessible. Some startups are offering online prescriptions for the drug, potentially making it too easily available. This article explores the challenges and controversies surrounding the availability of semaglutide for weight loss.
Yazen offers a comprehensive approach to weight loss that focuses on weight stability over time. Through our service and platform, our customers have access to medical professionals, including doctors, dietitians, personal trainers, and psychologists.
We combine this expert support with modern medications like Ozempic, known for its effectiveness in aiding weight loss. Yazen's approach involves ongoing monitoring and support, ensuring that individuals not only lose weight but also maintain their new weight in the long term. With a team of specialists and continuous follow-up, Yazen helps users make necessary lifestyle changes for sustained, stable weight loss over time.
Stay informed about the evolving landscape of weight-loss treatments and seize the opportunities it presents.
Read the full article on Sifted
More news
WOD26: Data Reveals Persistent Shame & Stigma Around Obesity Treatment
Ahead of World Obesity Day on 4 March, Yazen is sharing new findings from internal patient data, revealing that shame and stigma remain major barriers to obesity care — even as effective medical treatments become more widely available.
Yazen achieved record-breaking growth in 2025, doubling its revenue.
In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.
